Published in Am J Pathol on April 15, 2010
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Wnt signaling in cancer. Cold Spring Harb Perspect Biol (2012) 2.75
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Drugging Wnt signalling in cancer. EMBO J (2012) 1.63
The way Wnt works: components and mechanism. Growth Factors (2012) 1.37
Key signaling nodes in mammary gland development and cancer: β-catenin. Breast Cancer Res (2010) 1.24
N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med (2012) 1.24
Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer (2011) 1.23
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proc Natl Acad Sci U S A (2015) 1.20
ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol (2014) 1.19
WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol Med (2013) 1.17
Frizzled7 as an emerging target for cancer therapy. Cell Signal (2011) 1.16
Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev (2014) 1.15
Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther (2015) 1.14
Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse. PLoS One (2012) 1.14
From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer. Cell Res (2011) 1.12
Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc Natl Acad Sci U S A (2013) 1.11
The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancers. Mol Cell Biol (2010) 1.10
Wnt and mammary stem cells: hormones cannot fly wingless. Curr Opin Pharmacol (2010) 1.08
Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer (2010) 1.05
Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer (2013) 1.05
Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med (2013) 1.03
Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/β-catenin signaling. Cell Rep (2013) 1.03
The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer (2013) 1.02
Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prev Res (Phila) (2012) 1.01
S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res (2012) 1.01
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget (2015) 0.99
Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS One (2012) 0.96
Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med (2013) 0.96
Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis. Mol Cancer (2013) 0.96
Associations between TCF7L2 polymorphisms and risk of breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat (2012) 0.95
SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer. J Biol Chem (2013) 0.95
Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95
Wnt signaling in cancer. Oncogene (2016) 0.95
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci (2011) 0.94
Wnt/β-catenin Signaling in Normal and Cancer Stem Cells. Cancers (Basel) (2011) 0.94
Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS One (2012) 0.94
Vitamin D Is a Multilevel Repressor of Wnt/b-Catenin Signaling in Cancer Cells. Cancers (Basel) (2013) 0.93
Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS One (2013) 0.93
Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci (Landmark Ed) (2014) 0.92
Wnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer. Br J Cancer (2011) 0.90
Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis (2015) 0.90
MiR-199a regulates cell proliferation and survival by targeting FZD7. PLoS One (2014) 0.89
Paracrine signaling in mammary gland development: what can we learn about intratumoral heterogeneity? Breast Cancer Res (2014) 0.88
The PDZ protein TIP-1 facilitates cell migration and pulmonary metastasis of human invasive breast cancer cells in athymic mice. Biochem Biophys Res Commun (2012) 0.87
Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal (2012) 0.87
β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One (2015) 0.87
The roles of ncRNAs and histone-modifiers in regulating breast cancer stem cells. Protein Cell (2015) 0.87
Inactivation of RARβ inhibits Wnt1-induced mammary tumorigenesis by suppressing epithelial-mesenchymal transitions. Nucl Recept Signal (2014) 0.86
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
Apc mutation enhances PyMT-induced mammary tumorigenesis. PLoS One (2011) 0.86
Mammary cells with active Wnt signaling resist ErbB2-induced tumorigenesis. PLoS One (2013) 0.86
Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. Nat Commun (2016) 0.85
Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. PLoS One (2013) 0.84
Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation. Oncotarget (2015) 0.84
Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PLoS One (2013) 0.83
Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer (2013) 0.83
FH535 inhibited migration and growth of breast cancer cells. PLoS One (2012) 0.83
Regulation of the Wnt/β-Catenin Signaling Pathway by Human Papillomavirus E6 and E7 Oncoproteins. Viruses (2015) 0.83
Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med (2016) 0.82
Down-regulation of ANAPC13 and CLTCL1: Early Events in the Progression of Preinvasive Ductal Carcinoma of the Breast. Transl Oncol (2012) 0.82
Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin down-regulation. BMC Cancer (2013) 0.82
Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep (2015) 0.81
Crosstalk of the Insulin-Like Growth Factor Receptor with the Wnt Signaling Pathway in Breast Cancer. Front Endocrinol (Lausanne) (2015) 0.81
The prognostic significance of β-catenin, cyclin D1 and PIN1 in minor salivary gland carcinoma: β-catenin predicts overall survival. Eur Arch Otorhinolaryngol (2015) 0.80
Inhibition of Mouse Breast Tumor-Initiating Cells by Calcitriol and Dietary Vitamin D. Mol Cancer Ther (2015) 0.80
IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. Cancer Res (2014) 0.80
Ror2 regulates branching, differentiation, and actin-cytoskeletal dynamics within the mammary epithelium. J Cell Biol (2015) 0.80
Potential canonical wnt pathway activation in high-grade astrocytomas. ScientificWorldJournal (2012) 0.80
Mammary stem cells and cancer: roles of Wnt signaling in plain view. Breast Cancer Res (2010) 0.80
The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget (2015) 0.79
β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expression. Int J Clin Exp Pathol (2015) 0.79
Prognostic impact of the expression of Wnt-signaling proteins in cervical carcinoma FIGO stage I-IV treated with radiotherapy or chemoradiotherapy. Oncotarget (2016) 0.79
The tissue-specific stem cell as a target for chemoprevention. Stem Cell Rev (2011) 0.78
Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers. Oncotarget (2016) 0.78
Nuclear localizaiton of β-catenin is associated with poor survival and chemo-/radioresistance in human cervical squamous cell cancer. Int J Clin Exp Pathol (2014) 0.78
Twist-BRD4 complex: potential drug target for basal-like breast cancer. Curr Pharm Des (2015) 0.78
Simultaneous disruption of estrogen receptor and Wnt/β-catenin signaling is involved in methyl amooranin-mediated chemoprevention of mammary gland carcinogenesis in rats. Mol Cell Biochem (2013) 0.78
Wnt signaling in triple-negative breast cancer. Oncogenesis (2017) 0.78
Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Sci Rep (2017) 0.77
Newly Constructed Network Models of Different WNT Signaling Cascades Applied to Breast Cancer Expression Data. PLoS One (2015) 0.77
HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations. Clin Exp Metastasis (2015) 0.77
Mammary Development and Breast Cancer: A Wnt Perspective. Cancers (Basel) (2016) 0.77
Effect of glycogen synthase kinase-3 inactivation on mouse mammary gland development and oncogenesis. Oncogene (2014) 0.77
Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. PLoS One (2015) 0.76
Expression of β-catenin and cyclin D1 in Merkel cell carcinomas of the head and neck. Wien Klin Wochenschr (2013) 0.76
β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Mol Carcinog (2015) 0.76
Knockdown of eIF3D inhibits breast cancer cell proliferation and invasion through suppressing the Wnt/β-catenin signaling pathway. Int J Clin Exp Pathol (2015) 0.76
PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nat Commun (2016) 0.76
S-Nitrosation Mediates Multiple Pathways That Lead to Tumor Progression in Estrogen Receptor-Negative Breast Cancer. For Immunopathol Dis Therap (2012) 0.76
MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion. Oncotarget (2017) 0.76
High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression. BMC Cancer (2015) 0.76
The best of both worlds - managing the cancer, saving the bone. Nat Rev Endocrinol (2015) 0.75
Novel SUMO-Protease SENP7S Regulates β-catenin Signaling and Mammary Epithelial Cell Transformation. Sci Rep (2017) 0.75
Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium. Oncogene (2016) 0.75
Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukaemia. Sci Rep (2016) 0.75
Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling. Oncotarget (2016) 0.75
Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer. Biomark Res (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res (2008) 6.95
Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell (1988) 6.48
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
A random-effects ordinal regression model for multilevel analysis. Biometrics (1994) 5.28
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell (2004) 4.98
WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A (2007) 4.97
Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A (2000) 4.71
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A (2004) 3.95
The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell (1987) 3.78
Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol (2001) 3.26
Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo. Cells Tissues Organs (2007) 3.12
On mammary stem cells. J Cell Sci (2005) 2.56
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol (2002) 2.26
Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res (2003) 2.20
Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res (1990) 2.09
Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci (2007) 1.98
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol (2006) 1.96
Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res (2006) 1.91
Beta-catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia (2003) 1.68
E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol (1998) 1.61
Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res (2008) 1.58
Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J Pathol (2002) 1.53
Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis (2000) 1.52
Method for grading breast cancer. J Clin Pathol (1993) 1.46
A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol (2007) 1.36
Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol (2009) 1.32
Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol (2008) 1.28
Reciprocity between membranous and nuclear expression of beta-catenin in colorectal tumours. Virchows Arch (1997) 1.28
Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer (1999) 1.26
beta-Catenin and p53 analyses of a breast carcinoma tissue microarray. Cancer (2004) 1.23
Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol (2006) 1.22
Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol (2001) 1.16
The expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin and E-cadherin. Am J Pathol (1998) 1.12
Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. J Mol Histol (2007) 1.12
Expression patterns of beta-catenin in in situ and invasive breast cancer. Eur J Surg Oncol (2001) 1.12
Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLoS One (2009) 1.10
Intracellular distribution of beta-catenin in colorectal adenomas, carcinomas and Peutz-Jeghers polyps. J Cancer Res Clin Oncol (1999) 1.08
Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer (2002) 1.07
c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology (2000) 1.06
Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat (2005) 0.90
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 4.36
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med (2003) 3.78
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Preoperative clinic visits reduce operating room cancellations and delays. Anesthesiology (2005) 3.03
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer (2007) 3.02
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res (2006) 2.95
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol (2009) 2.88
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res (2006) 2.84
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
What is the most effective way to communicate results after endoscopy? Gastrointest Endosc (2007) 2.73
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med (2003) 2.73
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol (2011) 2.51
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res (2008) 2.35
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res (2002) 2.25
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23
Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst (2013) 2.21
Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med (2005) 2.18
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol (2007) 2.16
Treatment of cancer in sub-Saharan Africa. Lancet Oncol (2013) 2.07
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res (2007) 2.06
Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med (2006) 2.03
ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn (2012) 1.99
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol (2006) 1.98
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol (2006) 1.93
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol (2010) 1.90
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol (2008) 1.89
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer (2004) 1.85
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science (2009) 1.83
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet (2002) 1.80
Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol (2006) 1.76
Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am (2005) 1.76
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res (2005) 1.75
Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet (2010) 1.74
Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15. Hum Mutat (2010) 1.73
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res (2005) 1.71
Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology (2010) 1.70
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest (2008) 1.64
The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A (2004) 1.63
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol (2006) 1.60
Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res (2008) 1.59
Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology (2002) 1.58
Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys (2004) 1.57
Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol (2008) 1.56
X-ray fluorescence microscopy reveals large-scale relocalization and extracellular translocation of cellular copper during angiogenesis. Proc Natl Acad Sci U S A (2007) 1.55
Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc Natl Acad Sci U S A (2009) 1.52
High molecular weight polyethylene glycol (PEG 15-20) maintains mucosal microbial barrier function during intestinal graft preservation. J Surg Res (2013) 1.51
Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol (2011) 1.49
MYC in breast tumor progression. Expert Rev Anticancer Ther (2008) 1.49
Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol (2005) 1.49
Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol (2011) 1.45
The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res (2006) 1.43
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun (2013) 1.43
Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res (2011) 1.43
Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene (2003) 1.42
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med (2011) 1.42
Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment. J Digit Imaging (2008) 1.41
2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA (2012) 1.41
Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med (2007) 1.38
Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis (2012) 1.38
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res (2002) 1.33
The E2F3-Oncomir-1 axis is activated in Wilms' tumor. Cancer Res (2008) 1.33